NextCure, Inc. (NXTC): Operating Cash Flow
-$49.61M
Year ended 2025-12-31
-$36.98M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$49.61M | n/m | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | -$40.80M | n/m | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | -$52.97M | n/m | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | -$53.89M | n/m | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | -$57.28M | n/m | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | -$44.95M | n/m | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | -$35.62M | n/m | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | $7.99M | n/a | 2020-03-12, From 2018-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| NextCure, Inc. (NXTC) | 2025-12-31 | -$49.61M | n/m |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | -$35.25M | n/m |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | -$10.74M | n/m |
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | -$31.32M | n/m |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | -$14.77M | n/m |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | -$24.58M | n/m |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | -$66.44M | n/m |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | -$10.57M | n/m |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | -$29.76M | n/m |
Compare NXTC, IRD, COYA, UNCY side by side · Screen every company in Pharmaceutical Preparations ↗